MacroGenics Company Profile (NASDAQ:MGNX)

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MGNX
  • CUSIP: N/A
  • Web: www.macrogenics.com
Capitalization:
  • Market Cap: $638.97 million
  • Outstanding Shares: 35,012,000
Average Prices:
  • 50 Day Moving Avg: $19.76
  • 200 Day Moving Avg: $20.85
  • 52 Week Range: $16.75 - $33.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.95
  • P/E Growth: 0.02
Sales & Book Value:
  • Annual Revenue: $91.09 million
  • Price / Sales: 7.01
  • Book Value: $6.71 per share
  • Price / Book: 2.72
Profitability:
  • EBIDTA: ($59,800,000.00)
  • Net Margins: -55.01%
  • Return on Equity: -16.99%
  • Return on Assets: -14.99%
Debt:
  • Current Ratio: 14.34%
  • Quick Ratio: 14.34%
Misc:
  • Average Volume: 248,208 shs.
  • Beta: 2.8
  • Short Ratio: 12.56
 

Frequently Asked Questions for MacroGenics (NASDAQ:MGNX)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.09. The company earned $2.06 million during the quarter, compared to analysts' expectations of $5.88 million. MacroGenics had a negative return on equity of 16.99% and a negative net margin of 55.01%. View MacroGenics' Earnings History.

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?

12 brokerages have issued 1 year price objectives for MacroGenics' shares. Their predictions range from $22.00 to $52.00. On average, they expect MacroGenics' share price to reach $33.89 in the next twelve months. View Analyst Ratings for MacroGenics.

What are analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (5/9/2017)
  • 2. BTIG Research analysts commented, "Based upon the 4Q16 earnings call hosted last week and our follow-up conversation with management, we present an outline of expected activities during 2017. The majority of the MGNX portfolio will be entering or expanding Phase 1 studies during 2017, which will weigh potential clinical catalysts towards 2H2017 and early 2018. The most significant identified clinical read-out during 2017 will likely be the futility analysis from the Margetuximab pivotal study. We reiterate our Buy Rating but lower our Price Target to $28 from $35 as we push out Margetuximab sales expectations until 2021. A summary of events for 2017 is charted on Page 2 of this report." (3/6/2017)
  • 3. Cowen and Company analysts commented, "MGNX reported 4Q16 results and provided a pipeline update." (3/1/2017)
  • 4. Instinet analysts commented, "We are initiating coverage of MacroGenics with a Buy rating and $41 target price. We recommend accumulating MGNX shares in 2017, as we anticipate several data sets across programs, specifically for the company's B7-H3 franchise. We expect data cross multiple tumor types from ongoing basket trials of both enoblituzumab and bispecific counterpart MGD009 to define initial market opportunities that represent upside to current estimates." (3/1/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's relatively quiet 4Q16 earnings announcement/call was expected following the comprehensive pipeline update provided at the December 2016 R&D Day. The specific timing and magnitude of incremental news flow from both wholly-owned and partnered programs throughout FY17 still remains a bit uncertain ' but we anticipate the finalization of dose and administration schedules for a variety of DART programs to allow for the initiation of dose expansion cohorts in both FY17 and beyond. SOPHIA enrollment appears to remain on track and a newly-implemented trial amendment allowing for Kadcyla-na??ve patients should facilitate the pace of enrollment and eventually expand the addressable market opportunity. We continue to find valuation attractive here. Reduced target price of $42 (previously $51) reflects higher FY17 and forward-year OpEx ' coupled with reduced longer-term collaborative revenue estimates." (3/1/2017)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

  • Paulo F. Costa, Independent Chairman of the Board
  • Scott Koenig M.D., Ph.D., President, Chief Executive Officer, Director
  • James Karrels MBA, Chief Financial Officer, Vice President, Secretary
  • Ezio Bonvini M.D., Senior Vice President - Research, Chief Scientific Officer
  • Atul Saran, Senior Vice President, General Counsel
  • Eric Risser, Senior Vice President - Business Development and Portfolio Management
  • Kathryn E. Stein Ph.D., Senior Vice President- Product Development & Regulatory Affairs
  • Jon Marc Wigginton, Senior Vice President - Clinical Development and Chief Medical Officer
  • Lynn Cilinski, Vice President, Controller, Treasurer
  • Karen Jean Ferrante M.D., Director

Who owns MacroGenics stock?

MacroGenics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.13%), OppenheimerFunds Inc. (9.50%), BB Biotech AG (6.46%), Blue Ridge Capital L.L.C. (3.88%), Vanguard Group Inc. (3.87%) and Point72 Asset Management L.P. (3.37%). Company insiders that own MacroGenics stock include Ezio Bonvini, Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa. View Institutional Ownership Trends for MacroGenics.

Who sold MacroGenics stock? Who is selling MacroGenics stock?

MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, FMR LLC, TFS Capital LLC, Morgan Stanley, UBS Asset Management Americas Inc., Point72 Asset Management L.P., Oxford Asset Management and Spark Investment Management LLC. Company insiders that have sold MacroGenics stock in the last year include Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.

Who bought MacroGenics stock? Who is buying MacroGenics stock?

MacroGenics' stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, OppenheimerFunds Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Bellevue Group AG, State Street Corp, Renaissance Technologies LLC and Hood River Capital Management LLC. View Insider Buying and Selling for MacroGenics.

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MacroGenics stock can currently be purchased for approximately $18.25.


MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $33.89 (85.69% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Morgan StanleyLower Price TargetEqual Weight$24.00 -> $22.00LowView Rating Details
3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$26.00HighView Rating Details
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 -> $28.00N/AView Rating Details
3/1/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
3/1/2017Stifel NicolausReiterated RatingBuy$51.00 -> $42.00N/AView Rating Details
1/25/2017Citigroup IncLower Price TargetNeutral$32.00 -> $24.00N/AView Rating Details
12/19/2016SunTrust Banks, Inc.Initiated CoverageBuy$30.00N/AView Rating Details
11/3/2016WedbushReiterated RatingOutperform$52.00N/AView Rating Details
6/14/2016Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00N/AView Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for MacroGenics (NASDAQ:MGNX)
Earnings by Quarter for MacroGenics (NASDAQ:MGNX)
Earnings History by Quarter for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MacroGenics (NASDAQ:MGNX)
2017 EPS Consensus Estimate: ($4.17)
2018 EPS Consensus Estimate: ($3.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.18)($0.83)($1.03)
Q2 20174($1.17)($0.83)($1.03)
Q3 20174($1.21)($0.85)($1.04)
Q4 20174($1.24)($0.88)($1.07)
Q1 20181($0.96)($0.96)($0.96)
Q2 20181($0.90)($0.90)($0.90)
Q3 20181($0.93)($0.93)($0.93)
Q4 20181($0.96)($0.96)($0.96)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MacroGenics (NASDAQ:MGNX)
Insider Ownership Percentage: 6.78%
Institutional Ownership Percentage: 81.68%
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.00View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.00View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.68View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MacroGenics (NASDAQ:MGNX)
Latest Headlines for MacroGenics (NASDAQ:MGNX)
Source:
DateHeadline
finance.yahoo.com logoMacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 22, 2017
finance.yahoo.com - May 22 at 10:10 AM
seekingalpha.com logoMacroGenics (MGNX) Presents At BofAML 2017 Global Metals, Mining and Steel Conference
seekingalpha.com - May 19 at 11:53 PM
americanbankingnews.com logo Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $5.01 Million
www.americanbankingnews.com - May 10 at 11:34 AM
finance.yahoo.com logoMacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 9, 2017
finance.yahoo.com - May 9 at 11:49 AM
americanbankingnews.com logoZacks Investment Research Upgrades MacroGenics Inc (MGNX) to "Hold"
www.americanbankingnews.com - May 9 at 7:16 AM
americanbankingnews.com logoMacroGenics Inc (MGNX) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - May 8 at 8:30 PM
finance.yahoo.com logoETFs with exposure to MacroGenics, Inc. : May 8, 2017
finance.yahoo.com - May 8 at 6:05 PM
americanbankingnews.com logoMacroGenics Inc (MGNX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 8 at 11:10 AM
americanbankingnews.com logo-$1.05 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - May 8 at 10:48 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for MacroGenics Inc Increased by Wedbush (MGNX)
www.americanbankingnews.com - May 8 at 8:27 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for MacroGenics Inc (MGNX) Issued By Leerink Swann
www.americanbankingnews.com - May 8 at 8:27 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for MacroGenics Inc Lifted by Analyst (MGNX)
www.americanbankingnews.com - May 8 at 8:15 AM
finance.yahoo.com logoMacroGenics, Inc. :MGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 6:49 PM
americanbankingnews.com logoBrokers Offer Predictions for MacroGenics Inc's Q1 2018 Earnings (MGNX)
www.americanbankingnews.com - May 5 at 5:32 PM
finance.yahoo.com logoMacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 5:36 PM
finance.yahoo.com logoMacroGenics reports 1Q loss
finance.yahoo.com - May 3 at 5:36 PM
finance.yahoo.com logoInvestor Network: MacroGenics, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 9:22 AM
americanbankingnews.com logoMacroGenics (MGNX) Earns News Sentiment Rating of -0.07
www.americanbankingnews.com - May 2 at 9:34 PM
americanbankingnews.com logoMacroGenics (MGNX) Earns Media Impact Score of 0.10
www.americanbankingnews.com - April 27 at 11:44 PM
finance.yahoo.com logoMacroGenics Announces Registered Direct Offering of Common Stock
finance.yahoo.com - April 27 at 9:32 AM
finance.yahoo.com logoMacroGenics to Present at Two Upcoming Investor Conferences in May
finance.yahoo.com - April 26 at 6:47 PM
finance.yahoo.com logoMacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
finance.yahoo.com - April 25 at 5:50 PM
americanbankingnews.com logoMacroGenics (MGNX) Receiving Very Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 2:58 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Affect MacroGenics (MGNX) Share Price
www.americanbankingnews.com - April 22 at 12:38 AM
americanbankingnews.com logoMacroGenics Inc (MGNX) SVP Jon Marc Wigginton Sells 15,000 Shares
www.americanbankingnews.com - April 20 at 7:48 PM
finance.yahoo.com logoMacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : April 19, 2017
finance.yahoo.com - April 19 at 6:36 PM
americanbankingnews.com logoMacroGenics Inc (MGNX) Expected to Announce Quarterly Sales of $5.88 Million
www.americanbankingnews.com - April 19 at 11:56 AM
americanbankingnews.com logoMacroGenics (MGNX) Earning Somewhat Negative Media Coverage, Study Shows
www.americanbankingnews.com - April 18 at 2:00 PM
finance.yahoo.com logoMacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : April 18, 2017
finance.yahoo.com - April 18 at 10:25 AM
americanbankingnews.com logoMacroGenics Inc (MGNX) Expected to Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - April 17 at 9:26 AM
americanbankingnews.com logoMacroGenics (MGNX) Given Daily Coverage Optimism Score of -0.15
www.americanbankingnews.com - April 15 at 12:11 PM
americanbankingnews.com logoMacroGenics Inc (MGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 11 at 9:15 AM
globenewswire.com logoMacroGenics to Present at the Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 31 at 6:37 PM
streetinsider.com logoMacrogenics (MGNX) Says Eight Posters Based on MacroGenics-developed Molecules Featured at AACR - StreetInsider.com
www.streetinsider.com - March 31 at 6:37 PM
americanbankingnews.com logoMacroGenics Inc (MGNX) Now Covered by Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - March 31 at 12:38 PM
streetinsider.com logoMacrogenics (MGNX) Says Eight Posters Based on MacroGenics-developed Molecules Featured at AACR
www.streetinsider.com - March 31 at 9:39 AM
finance.yahoo.com logoEight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017
finance.yahoo.com - March 31 at 9:39 AM
finance.yahoo.com logoMacroGenics to Present at the Needham Healthcare Conference
finance.yahoo.com - March 29 at 7:09 PM
finance.yahoo.com logoMACROGENICS INC Financials
finance.yahoo.com - March 7 at 6:17 PM
us.rd.yahoo.com logoCoverage initiated on MacroGenics by Instinet
us.rd.yahoo.com - March 2 at 6:44 PM
biz.yahoo.com logoMACROGENICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 1 at 10:55 AM
biz.yahoo.com logoMACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 1 at 10:55 AM
finance.yahoo.com logoEdited Transcript of MGNX earnings conference call or presentation 28-Feb-17 9:30pm GMT
finance.yahoo.com - March 1 at 10:55 AM
finance.yahoo.com logoMacroGenics Provides Update on Corporate Progress and 2016 Financial Results
finance.yahoo.com - February 28 at 6:39 PM
biz.yahoo.com logoQ4 2016 MacroGenics Inc Earnings Release - After Market Close
biz.yahoo.com - February 28 at 10:08 AM
finance.yahoo.com logoMacroGenics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - February 27 at 6:06 PM
finance.yahoo.com logoMacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call
finance.yahoo.com - February 16 at 6:07 PM
globenewswire.com logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 10 at 12:40 AM
finance.yahoo.com logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 7:32 PM
biz.yahoo.com logoMACROGENICS INC Files SEC form 8-K, Financial Statements and Exhibits
biz.yahoo.com - January 26 at 9:27 PM

Social

Chart

MacroGenics (MGNX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff